Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunovion
• Treatments: Eszopiclone

Criteria

• Subjects, between the ages of 18 and 64 years inclusive

• Subjects with Generalized Anxiety Disorder (GAD)

• Subjects with insomnia related to GAD.